Mehmet Colak

Mehmet Colak

Auto-generated profile, based on publicly available information

Mehmet Colak

Department of Pharmacology, Faculty of Medicine, Inonu University, Malatya, Turkey

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2026 in Journal of Molecular Histology
Verified
Journal Article
Closed access
PDF file
Onural OzhanOnural Ozhan
Onural Ozhan
MCMehmet Colak
Mehmet Colak
EKElif Karaca
Elif Karaca
FDFeyzi Doğru
Feyzi Doğru
ZKZeynep Kucukakcali
Zeynep Kucukakcali
HPHakan Parlakpinar
Hakan Parlakpinar

26 December 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Onural OzhanOnural Ozhan
Onural Ozhan
MCMehmet Colak
Mehmet Colak
AYAzibe Yıldız
Azibe Yıldız
MDMerve Durhan
Merve Durhan
NVNigar Vardi
Nigar Vardi
HPHakan Parlakpinar
Hakan Parlakpinar
Ciprofloxacin (CFX), a fluoroquinolone antibiotic, is known to induce oxidative stress–mediated cardiotoxicity. This study investigates the potential protective and therapeutic effects of apocynin (APO), a selective NADPH oxidase (NOX) inhibitor and potent antioxidant, against CFX-induced myocardial injury in rats. Thirty-two male Wistar albino rats were randomly divided into four groups (n = 8). CFX (25 mg/kg, i.p.) was administered twice daily for one week, while APO (20 mg/kg, i.p.) was given once daily for four days either before or after CFX treatment. Hemodynamic parameters (heart rate, systolic, diastolic, and mean blood pressures) and electrocardiographic (ECG) indices (PR, QRS, and QT intervals) were recorded invasively. Histopathological evaluations assessed myocardial inflammation, cardiomyocyte degeneration, and aortic intima–media thickness. Biochemical analyses of cardiac and aortic tissues included measurements of malondialdehyde (MDA), glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT) levels. CFX administration significantly elevated cardiac MDA by ~ 45% and decreased SOD and CAT activities by ~ 30–35% (p < 0.05) compared with controls. These alterations were markedly attenuated in APO-treated rats, where antioxidant enzyme activities increased by ~ 25–40% and MDA levels were restored toward normal values (p < 0.05 vs. CFX). APO also shortened the QT interval by ~ 15% and improved systolic pressure by ~ 12% compared with the CFX group (p < 0.05). Histopathological findings confirmed reduced myocardial degeneration and inflammatory infiltration in both APO + CFX and CFX + APO groups. APO effectively ameliorated CFX-induced cardiac oxidative injury by inhibiting NOX2-mediated reactive oxygen species formation and restoring antioxidant defense mechanisms, leading to functional improvement in ECG and hemodynamic parameters. These results suggest that targeted NOX inhibition may represent a practical pharmacological approach to reduce fluoroquinolone-associated cardiotoxicity, warranting further translational investigation.

29 September 2025 in BMC Urology
Verified
Journal Article
Open access
PDF file
Onural OzhanOnural Ozhan
Onural Ozhan
MCMehmet Colak
Mehmet Colak
EKElif Karaca
Elif Karaca
FDFeyzi Doğru
Feyzi Doğru
ZKZeynep Kucukakcali
Zeynep Kucukakcali
HPHakan Parlakpinar
Hakan Parlakpinar
This study investigated the renoprotective effects of compound 21 (C21) and empagliflozin (EMPA) individually and in combination in an Nω-Nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rat model. The objective of this study was to evaluate their impact on oxidative stress (OS), biochemical markers, and histopathological changes in renal tissues. Male Sprague–Dawley rats were divided into five groups: control, hypertension (HT), HT + C21, HT + EMPA, and HT + C21 + EMPA. Hypertension was induced by intraperitoneal L-NAME administration. Biochemical analyses of kidney tissue and histopathological evaluations were conducted to assess the treatment effects. Both C21 and EMPA significantly reduced the levels of OS markers, such as malondialdehyde, while increasing the levels of antioxidants, such as total antioxidants and glutathione. Compared with the individual treatments, the combination of C21 and EMPA exhibited superior efficacy in mitigating OS by significantly increasing superoxide dismutase and glutathione peroxidase activities. Furthermore, these treatments alleviated histopathological damage, including glomerular collapse, tubular degeneration, and interstitial inflammation, which were prominent in the HT group. The combined therapy group presented nearly normal histological structures in kidney tissues, with reduced inflammation and cellular damage. Urinary biochemical markers also reflected improved renal function in the treated groups, particularly in the combined therapy group. These findings indicate that the synergistic effects of C21 and EMPA enhance their protective impact on renal tissues. C21 and EMPA demonstrated significant renoprotective effects in this HT model by reducing OS, enhancing antioxidant defenses, and mitigating renal tissue damage. Their combined administration offered synergistic benefits, highlighting their potential as a therapeutic strategy for hypertension-induced renal injury. Further research is warranted to validate these findings in clinical settings.